Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (191-200 of 282) with videos related to

Pageof 29
Sort By:
European Urology Open Science|April 21, 2025
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)Brendan J Guercio, Karissa Whiting, Ronak H Shah, et al.
Journal of the National Cancer Institute|June 18, 2010
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerJudy E Garber, Susan Halabi, Sara M Tolaney, et al.
Genes, Chromosomes & Cancer|November 10, 2019
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancerSantosh Gupta, Daniel H Hovelson, Gabor Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerWanling Xie, Meredith M Regan, Marc Buyse, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
CA: a Cancer Journal for Clinicians|January 20, 2016
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineMichael W Kattan, Kenneth R Hess, Mahul B Amin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trialJosé C Valentín López, Chenxi Yu, Todd P Knutson, et al.
European Urology|May 22, 2024
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized TrialsPraful Ravi, Wanling Xie, Marc Buyse, et al.
European Urology|August 7, 2025
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate CancerSusan Halabi, Siyuan Guo, Bin Luo, et al.
JCO Precision Oncology|June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry StudyGordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
Pageof 29

Showing results (191-200 of 282) with videos related to

Sort By:
Pageof 29
European Urology Open Science|April 21, 2025
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)Brendan J Guercio, Karissa Whiting, Ronak H Shah, et al.
Journal of the National Cancer Institute|June 18, 2010
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerJudy E Garber, Susan Halabi, Sara M Tolaney, et al.
Genes, Chromosomes & Cancer|November 10, 2019
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancerSantosh Gupta, Daniel H Hovelson, Gabor Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerWanling Xie, Meredith M Regan, Marc Buyse, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
CA: a Cancer Journal for Clinicians|January 20, 2016
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineMichael W Kattan, Kenneth R Hess, Mahul B Amin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trialJosé C Valentín López, Chenxi Yu, Todd P Knutson, et al.
European Urology|May 22, 2024
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized TrialsPraful Ravi, Wanling Xie, Marc Buyse, et al.
European Urology|August 7, 2025
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate CancerSusan Halabi, Siyuan Guo, Bin Luo, et al.
JCO Precision Oncology|June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry StudyGordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
Pageof 29